American Bio Medica (American Bio Medica) Risk Assessment

View and export this data going back to . Start your Free Trial

What is American Bio Medica Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of American Bio Medica is: No Data: Cannot be evaluated.

Competitive Comparison of American Bio Medica's Risk Assessment

For the Diagnostics & Research subindustry, American Bio Medica's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

American Bio Medica's Risk Assessment Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, American Bio Medica's Risk Assessment distribution charts can be found below:

* The bar in red indicates where American Bio Medica's Risk Assessment falls into.

American Bio Medica (OTCPK:ABMC) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

American Bio Medica Risk Assessment Related Terms

Thank you for viewing the detailed overview of American Bio Medica's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

American Bio Medica (American Bio Medica) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » American Bio Medica Corp (OTCPK:ABMC) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

122 Smith Road, Kinderhook, New York, NY, USA, 12106

Website

https://www.abmc.com

American Bio Medica Corp is a us-based company engaged in manufacturing and selling lateral flow immunoassay tests, primarily for the immediate detection of certain drugs in urine and oral fluids at the point of collection. It also manufactures and sells drug testing products and provides bulk test strip manufacturing services to unaffiliated third parties on a contract basis. The company offers few urine tests which include Rapid Drug Screen, RDS InCup, Rapid TOX, and Rapid TOX Cup II. Its target customer includes workplace, government, corrections, clinical and educational markets. Geographically, it derives a majority of revenue from the United States.

Executives

Stuart Steinberg	10 percent owner	85 BELLEVUE AVENUE, RYE NY 10580
John J Moroney	10 percent owner	118 PEGASUS DR., JUPITER FL 33477
Chaim Davis	director	2601 PINE TREE DRIVE, MIAMI BEACH FL 33140
Peter Jerome	director	7 RIDGECREST AVE, LATHAM NY 12110
Diane Generous	director	122 SMITH ROAD, KINDERHOOK NY 12106
Melissa A Waterhouse	officer: EVP, CCO, CORP SEC	AMERICAN BIO MEDICA CORPORATION, 122 SMITH ROAD, KINDERHOOK NY 12106
Mp Biomedicals Llc	10 percent owner	3 HUTTON CENTRE DRIVE, SUITE 100, SANTA ANA CA 92707
Douglas Casterlin	officer: Executive Vice President	C/O MELISSA A. WATERHOUSE/ABMC, 122 SMITH ROAD, KINDERHOOK NY 12106
Jean Neff	director	C/O ABMC, 122 SMITH ROAD, KINDERHOOK NY 12106
Stefan Parker	officer: Chief Financial Officer	122 SMITH ROAD, KINDERHOOK NY 12106
Carl A Florio	director	C/O HUDSON RIVER BANK & TRUST CO, PO BOX 76, HUDSON NY 12534
Stan Cipkowski	director	300 S LAKE DR, STE 340, FISHKILL NY 12553
Anthony G Costantino	director	122 SMITH ROAD, KINDERHOOK NY 12106
Edmund M Jaskiewicz	director, officer: President
Richard Koskey	director	C/O ABMC 122 SMITH ROAD, 122 SMITH ROAD, KINDERHOOK NY 12106